Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference
Catalyst rich 2021 includes expected topline readouts from ten clinical trials across the Company’s depression, neurology and neuropsychiatry franchises and in COVID-related ARDS Company committed to accelerating pipeline and expanding product engine with goal of delivering at least two
View HTML
Toggle Summary Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics Announces the Appointment of Barry Greene as CEO
Barry Greene , a world-class leader with global experience and a significant track record of success in R&D and commercialization, joins as part of plan to accelerate the Sage mission to deliver truly transformational medicines for people with brain health disorders Jeff Jonas to assume new role of
View HTML
Toggle Summary Sage Therapeutics to Present at BMO 2020 Growth & ESG Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S. , excluding rights to zuranolone in Japan , Taiwan and South Korea Sage
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
Ongoing zuranolone Phase 3 pivotal trials in major depression and postpartum depression progressing well; expect to initiate dosing in CORAL Study in 4Q 2020 Continued execution across brain health franchises highlighted during 2 nd annual FutureCast event First patient dosed in PARADIGM Study
View HTML
Toggle Summary Sage Therapeutics to Present at Upcoming November Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2020-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas , M.D.,
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD
Zuranolone was generally well-tolerated at the 30 mg dose and by the initial patients treated with the 50 mg dose with an adverse event profile consistent with that seen in earlier trials Nearly half of trial participants with positive response to initial 14-day course of zuranolone 30 mg did not
View HTML